The authority has taken the decision based on a letter submitted by the Committee headed by Dr S Eswara Reddy, Joint Drug Controller, CDSCO. It states, “NPPA may continue with the increased ceiling price for Heparin Injection 5000IU/ml, to ensure continuous availability of this essential drug.
The letter further added that recent spurt in the number of cases in some states may also lead to higher demand for the drug. And the ceiling price of Heparin may be reviewed after the C-19 situation becomes normal or earlier as deemed fit.”
Also read | Oseltamivir & Zanamivir to be included in Sch-H1
Based on the committee’s opinion, the NPPA authority deliberated upon the matter in detail and looking at the availability of Heparin Injection 1000IU/ ml and Heparin Injection 5000IU/ ml, a scheduled formulation, especially during the pandemic situation of C-19, felt that any situation of non-availability due to increase in the price of API needs to be seen from a public interest perspective.
“Due to an extraordinary situation, the Authority decided to extend the revised ceiling price of Heparin Injection 5000IU/ml and 1000 IU/ml fixed vide SO. 2151(E) dated 30.06.2020 up to 31.03.2021, in the public interest.
To download notification No. SO. 2151(E) dated 30.06.2020, click here
The Authority further directed that the provisions of para 13(2) of DPCO 2013 would not be applicable on the revised ceiling price of Heparin 1000IU/ml Injection and Heparin 5000IU/ml Injection up to 31st March 2021,” stated in the NPPA’s minutes of the meeting.